# Stairmed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stairmed

- Industry: Healthcare Specialists
- Headquarters: Shanghai, China
- Website: www.stairmed.com/
- Total disclosed funding: $48M
- Latest round: Series B (Dec 17, 2025)
- Investors on record: 6

## About

Based in Shanghai, China and established in 2021, Shanghai Stairmed Technology Co., Ltd., trading as Stairmed, is a company engaged in the development of implantable brain-computer interface technology to connect the human brain to the outside world. The company's founder, Zhengtuo Zhao, is a scientist who has published research on Ultraflexible electrode arrays for months-long high-density electrophysiological mapping of thousands of neurons in rodents. In March 2026, Stairmed raised CNY 500 million in strategic investment led by Alibaba Ventures, with participation from SDIC Unity Capital, Tencent Investment, Source Code Capital, FountainBridge Capital, OrbiMed Advisors, Oriza Holdings, Qiming Venture Partners, Lilly Asia Ventures, and Shanghai State-owned Capital Investment Leading Fund.

The company comprehensively analyzes and understands the brain, thus realizing the two-way interaction between the brain and peripherals by establishing a high-bandwidth information channel between the human brain and the outside world. The company's technology and products can be applied in the direction of human function repair, disease treatment, and human function enhancement. At the hardware level, the company has applied the concept of "ultra-flexible electrodes" to reduce the size of electrodes invading the brain.

Stairmed generates revenue by providing BCI system products to medical institutions, charging technology - transfer fees to partners, and offering R&D services for customized BCI-related projects.

## Funding rounds

- Series B, Dec 17, 2025 — Shanghai State-owned Capital Investment Leading Fund
- Series B, Feb 10, 2025, $48M — OrbiMed Advisors, Qiming Venture Partners, Lilly Asia Ventures, FountainBridge Capital
- Series A, Dec 30, 2022 — OrbiMed Advisors, Oriza Holdings
- Angel, Dec 16, 2022 — FountainBridge Capital

## Investors

- FountainBridge Capital (https://capitalatlas.ai/funds/fountainbridge-capital) — Angel, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Shanghai State-owned Capital Investment Leading Fund (https://capitalatlas.ai/funds/shanghai-state-owned-capital-investment-leading-fund) — Series B